MEDTECH has reached an important milestone, with the completion of 100 spinal surgeries with ROSA Spine, its robotic-assistive device for minimally invasive surgery of the spine. ROSA Spine received the CE Mark in 2014 and was granted U.S. FDA 510(k) clearance in January 2016.
MEDTECH: 100 Surgeries With ROSA Spine
1 min read Premium comments
Secondary
Surgeries utilizing ROSA Spine have been performed by:
- Michel Lefranc, a neurosurgeon at Amiens-Picardy University Hospital (France),
- Michael Winking at Klinikum Osnarbrück (Germany),
- Juan Torres-Reveron at Miami Valley Hospital in Dayton, Ohio (United States),
- Carlos Botella at Hospital La Fe à Valencia (Spain).
The 100th case was performed by Dr. Michel Lefranc. “Having performed several procedures with ROSA Spine, I have been extremely pleased with its accuracy and versatility, ” said Dr. Lefranc in the May 11, 2016 news release. “The assistance of the robot allows the surgeon to perform the surgery as it was previously planned.”
“The 100th ROSA Spine procedure is a significant milestone for our Company that only scratches the surface of the potential opportunities for our ROSA robotic surgery system, ” said Bertin Nahum, CEO and founder of Medtech. “This achievement continues to further validate our technology as an innovative approach in the spine market.”
Dr. Lefranc told OTW, “The patient had a fracture of the spine (L4). The aim was to use a minimally invasive approach by placing the intra-corporeal implant associated with the implementation of acrylic cement. This is an image-guided surgery of which the most interesting part is the target of transpedicular of two intra-corporeal implants.”
“The interest and the challenge of this surgery is to place implants to optimize the spinal restoration (restoring vertebral height and a good reduction of the fracture). The other difficulty is that the target pedicle, which is the intrusion cortical pedicle, could cause a breach of lumbar nerve roots.”
“In this surgery, the robot allowed us to optimize the placement of implants through the intraoperative 3D planning, to reduce the overall procedure time. In this case, this allowed the patient to be released and back home the day after surgery.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.